Breast Clinical Trial

Breast Study

(Double Blind Placebo Controlled)
60 were enrolled, with an initial diagnoses of moderate to severe Stage I to Stage IV, Malignant Carcinoma in the Breast Tissue. Each diagnoses was confirmed by a Fine Needle Aspiration Biopsy (FNAB) or Breast Biopsy (BB), and an MRI. Participants were randomly assigned to one of three groups. The first group took ReaLife+TM. The second took a placebo. The third took nothing. No patient received surgery, chemo or radiation before or during the Clinical Trial. Each Patient in Group 1, took 1 packet of ReaLife+TM twice daily, mixed with water or juice.


The information on this site is provided as an information resource only and is not to be used or relied on for any diagnostic or treatment purposes.